详情页 - 昆明医科大学第一附属医院知识库

当前位置：首页 > 详情页

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

113| 认领 | 链接全文 |

文献详情

编号/登记号：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究类型：

研究参与人：

研究单位： [1]Department of Hematology, Xinqiao Hospital ChongQing, Chongqing, China, 400037 [2]Gracell Biotechnology Shanghai Co., Ltd. [3]920th Hospital of Joint Logistics Support Force of People's Liberation Army of China [4]The Second Affiliated Hospital of Chongqing Medical University [5]The Affiliated Hospital Of Guizhou Medical University [6]Central South University [7]First Affiliated Hospital of Kunming Medical University [8]The General Hospital of Western Theater Command [9]Second Affiliated Hospital of Xi'an Jiaotong University [10]Nanfang Hospital of Southern Medical University [11]Fujian Medical University Union Hospital [12]The First Affiliated Hospital of Anhui Medical University [13]Tang-Du Hospital

研究目的：

The stunning response rate of anti-CD19(cluster of differentiation antigen 19) auto-CAR(chimeric antigen receptor)-T cell therapy brings hope to patients with relapsed or refractory B-cell hematologic malignancies. However, based on open clinical trials, using patients' T cells might encounter the failure of apheresis available T cells, even if successful, the time needed for the manufacture could also cause the irreversible disease progress. Furthermore, the cost of auto-CAR-T cells is not affordable for most patients. So to provide an accessible and affordable anti-CD19 CAR-T cell therapy for patients with B-cell hematologic malignancies, we launch such a trial that using the edited T cells from healthy donors to manufacture universal CAR-T cells and adapt it in patients with CD19+ B-cell leukemia or lymphoma.